Detailed information for compound 310002

Basic information

Technical information
  • TDR Targets ID: 310002
  • Name: 3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl )carbamoyl]-6-methoxyphenyl]-4-[[4,5-dihydro- 1,3-oxazol-2-yl(methyl)amino]methyl]thiophene -2-carboxamide
  • MW: 568.86 | Formula: C23H20Cl3N5O4S
  • H donors: 2 H acceptors: 3 LogP: 4.66 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: COc1cc(Cl)cc(c1NC(=O)c1scc(c1Cl)CN(C1=NCCO1)C)C(=O)Nc1ccc(cn1)Cl
  • InChi: 1S/C23H20Cl3N5O4S/c1-31(23-27-5-6-35-23)10-12-11-36-20(18(12)26)22(33)30-19-15(7-14(25)8-16(19)34-2)21(32)29-17-4-3-13(24)9-28-17/h3-4,7-9,11H,5-6,10H2,1-2H3,(H,30,33)(H,28,29,32)
  • InChiKey: FBXIHZSULWMHJY-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridyl)carbamoyl]-6-methoxy-phenyl]-4-[[4,5-dihydrooxazol-2-yl(methyl)amino]methyl]thiophene-2-carboxamide
  • 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridyl)amino]-oxomethyl]-6-methoxyphenyl]-4-[[4,5-dihydrooxazol-2-yl(methyl)amino]methyl]-2-thiophenecarboxamide
  • 3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxy-phenyl]-4-[[4,5-dihydro-1,3-oxazol-2-yl(methyl)amino]methyl]thiophene-2-carboxamide
  • 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridyl)carbamoyl]-6-methoxy-phenyl]-4-[[methyl(2-oxazolin-2-yl)amino]methyl]thiophene-2-carboxamide
  • 3-chloro-N-(4-chloro-2-(((5-chloro-2-pyridinyl)amino)carbonyl)-6-methoxyphenyl)-4-(((4,5-dihydro-2-oxazolyl)methylamino)methyl)-2-thiophenecarboxamide
  • 3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl]-4-[(4,5-dihydro-1,3-oxazol-2-yl-methylamino)methyl]thiophene-2-carboxamide
  • 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridyl)carbamoyl]-6-methoxy-phenyl]-4-[(4,5-dihydrooxazol-2-yl-methyl-amino)methyl]thiophene-2-carboxamide
  • 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridyl)amino]-oxomethyl]-6-methoxyphenyl]-4-[(4,5-dihydrooxazol-2-yl-methylamino)methyl]-2-thiophenecarboxamide
  • 3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxy-phenyl]-4-[(4,5-dihydro-1,3-oxazol-2-yl-methyl-amino)methyl]thiophene-2-carboxamide
  • 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL)AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL)METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE
  • XLD

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens coagulation factor X Starlite/ChEMBL References
Homo sapiens cathepsin G Starlite/ChEMBL References
Homo sapiens protease, serine, 1 (trypsin 1) References
Homo sapiens protease, serine, 3 Starlite/ChEMBL References
Homo sapiens protease, serine, 2 (trypsin 2) References
Rattus norvegicus Coagulation factor X Starlite/ChEMBL References
Homo sapiens plasminogen Starlite/ChEMBL References
Homo sapiens plasminogen activator, urokinase Starlite/ChEMBL References
Homo sapiens coagulation factor XI Starlite/ChEMBL References
Homo sapiens coagulation factor II (thrombin) Starlite/ChEMBL References
Homo sapiens plasminogen activator, tissue Starlite/ChEMBL References
Homo sapiens kallikrein B, plasma (Fletcher factor) 1 Starlite/ChEMBL References
Homo sapiens elastase, neutrophil expressed Starlite/ChEMBL References
Homo sapiens coagulation factor V (proaccelerin, labile factor) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) Get druggable targets OG5_126639 All targets in OG5_126639
Onchocerca volvulus Get druggable targets OG5_126639 All targets in OG5_126639
Toxoplasma gondii PAN domain-containing protein Get druggable targets OG5_134971 All targets in OG5_134971
Toxoplasma gondii PAN domain-containing protein Get druggable targets OG5_134971 All targets in OG5_134971
Schistosoma mansoni dock Get druggable targets OG5_126666 All targets in OG5_126666
Neospora caninum hypothetical protein Get druggable targets OG5_134971 All targets in OG5_134971
Echinococcus multilocularis Coagulation factor 5 8 type, C terminal Get druggable targets OG5_126666 All targets in OG5_126666
Schistosoma japonicum IPR010703,Dedicator of cytokinesis,domain-containing Get druggable targets OG5_126666 All targets in OG5_126666
Neospora caninum hypothetical protein Get druggable targets OG5_134971 All targets in OG5_134971
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_126639 All targets in OG5_126639
Echinococcus multilocularis dedicator of cytokinesis protein Get druggable targets OG5_126666 All targets in OG5_126666
Echinococcus granulosus Coagulation factor 5 8 type C terminal Get druggable targets OG5_126666 All targets in OG5_126666
Onchocerca volvulus Get druggable targets OG5_126639 All targets in OG5_126639
Schistosoma japonicum ko:K09639 transmembrane protease, serine 8, putative Get druggable targets OG5_126639 All targets in OG5_126639
Schistosoma japonicum Retinoschisin precursor, putative Get druggable targets OG5_126666 All targets in OG5_126666
Schistosoma japonicum IPR000421,Coagulation factor 5/8 type, C-terminal;IPR008979,Galactose-binding like,domain-containing Get druggable targets OG5_126666 All targets in OG5_126666
Schistosoma japonicum ko:K09639 transmembrane protease, serine 8, putative Get druggable targets OG5_126639 All targets in OG5_126639
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) Get druggable targets OG5_126639 All targets in OG5_126639
Brugia malayi Trypsin family protein Get druggable targets OG5_126639 All targets in OG5_126639
Neospora caninum hypothetical protein Get druggable targets OG5_134971 All targets in OG5_134971
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_126639 All targets in OG5_126639
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma mansoni cercarial elastase (S01 family) cathepsin G 255 aa 209 aa 25.8 %
Echinococcus granulosus transmembrane protease serine 3 elastase, neutrophil expressed 267 aa 236 aa 27.5 %
Echinococcus granulosus Mastin plasminogen activator, urokinase 414 aa 340 aa 24.4 %
Brugia malayi Trypsin family protein protease, serine, 1 (trypsin 1) 247 aa 287 aa 21.6 %
Schistosoma mansoni cercarial elastase (S01 family) protease, serine, 2 (trypsin 2) 247 aa 240 aa 25.8 %
Schistosoma mansoni cercarial elastase (S01 family) protease, serine, 3 261 aa 234 aa 25.2 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Kringle domain containing protein 0.0223 0.1255 0.1255
Loa Loa (eye worm) hypothetical protein 0.0946 1 1
Onchocerca volvulus 0.0826 0.8555 0.8555
Loa Loa (eye worm) TK/ROR protein kinase 0.0223 0.1255 0.1255
Echinococcus multilocularis tissue type plasminogen activator 0.0223 0.1255 1
Loa Loa (eye worm) hypothetical protein 0.0946 1 1
Echinococcus granulosus tissue type plasminogen activator 0.0223 0.1255 1
Plasmodium vivax cysteine repeat modular protein 1, putative 0.0223 0.1255 0.5
Schistosoma mansoni hypothetical protein 0.0223 0.1255 0.1255
Plasmodium falciparum cysteine repeat modular protein 1 0.0223 0.1255 0.5
Onchocerca volvulus 0.0223 0.1255 0.1255
Toxoplasma gondii PAN domain-containing protein 0.073 0.7386 1
Onchocerca volvulus 0.0946 1 1
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) 0.0946 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0223 0.1255 0.5
Loa Loa (eye worm) hypothetical protein 0.0223 0.1255 0.1255
Leishmania major hypothetical protein, conserved 0.0223 0.1255 0.5
Mycobacterium ulcerans hypothetical protein 0.0119 0 0.5
Brugia malayi Protein kinase domain containing protein 0.0223 0.1255 0.1255
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) 0.0946 1 1
Toxoplasma gondii PAN domain-containing protein 0.073 0.7386 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 0.35 uM Anticoagulant potency in dog plasma assessed as concentration for doubling of prothrombin time ChEMBL. 17536795
Activity (functional) = 0.36 uM Anticoagulant potency in human plasma assessed as concentration for doubling of prothrombin time ChEMBL. 17536795
Activity (functional) = 93 uM Anticoagulant potency in rat plasma assessed as concentration for doubling of prothrombin time ChEMBL. 17536795
CL (ADMET) = 5.8 ml/min.kg Clearance in beagle dog at 1 mg/kg, iv ChEMBL. 17536795
Cmax (ADMET) = 1.9 ug ml-1 Cmax in beagle dog at 10 mg/kg, po ChEMBL. 17536795
ED50 (functional) = 0.8 uM Effective dose required for antithrombotic activity in rat vena cava stasis model ChEMBL. 15013007
F (ADMET) = 40 % Oral bioavailability in dog ChEMBL. 15013007
F (ADMET) = 56 % Bioavailability in beagle dog at 10 mg/kg, po normalized to 1 mg/kg, iv ChEMBL. 17536795
Fold change (functional) = 3.2 Ex vivo anticoagulant potency in dog assessed as prolongation of prothrombin time at 10 mg/kg, po after 1 hr ChEMBL. 17536795
Fold change (functional) = 4 Ex vivo anticoagulant potency in dog assessed as prolongation of prothrombin time at 10 mg/kg, po after 6 hrs ChEMBL. 17536795
Fold change (functional) = 5 Ex vivo anticoagulant potency in dog assessed as prolongation of prothrombin time at 10 mg/kg, po after 2 hrs ChEMBL. 17536795
Ki (binding) = 0.007 nM Inhibition of human F10a ChEMBL. 17536795
Ki (binding) = 0.15 nM Inhibition of dog F10a ChEMBL. 17536795
Ki (binding) = 0.29 nM Inhibition of rat F10a ChEMBL. 17536795
Ki (binding) = 0.29 nM Inhibition of rat F10a ChEMBL. 17536795
Ki (binding) = 37 nM Inhibition of human kallikrein ChEMBL. 17536795
Ki (binding) = 37 nM Inhibition of human kallikrein ChEMBL. 17536795
Ki (binding) = 90 nM Inhibition of human F2a ChEMBL. 17536795
Ki (binding) > 5000 nM Inhibition of human tPA ChEMBL. 17536795
Ki (binding) > 5000 nM Inhibition of human urokinase ChEMBL. 17536795
Ki (binding) > 5000 nM Inhibition of human tPA ChEMBL. 17536795
Ki (binding) > 5000 nM Inhibition of human urokinase ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human trypsin ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human F11a ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human aPC ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human plasmin ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human chymotrypsin ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human cathepsin G ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human neutrophil elastase ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human trypsin ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human F11a ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human aPC ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human plasmin ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human cathepsin G ChEMBL. 17536795
Ki (binding) > 10000 nM Inhibition of human neutrophil elastase ChEMBL. 17536795
Ki app (binding) = 0.007 nM Inhibition of human F10a ChEMBL. 17536795
Ki app (binding) = 90 nM Inhibition of human F2a ChEMBL. 17536795
Ki app (binding) > 5000 nM Inhibition of bovine trypsin ChEMBL. 17536795
t1/2 (ADMET) = 3.2 hr Half life in beagle dog at 1 mg/kg, iv ChEMBL. 17536795
Vss (ADMET) = 1.6 L/Kg Volume of distribution at steady state in beagle dog at 1 mg/kg, iv ChEMBL. 17536795

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.